Q3 2025 Stoke Therapeutics Inc Earnings Call Transcript
Key Points
- Stoke Therapeutics Inc (STOK) has made significant progress in advancing its lead candidate, Zariva Nursen, through Phase 3 trials for Dravet syndrome, with over 200 patients identified for the study.
- The company has a strong financial position, ending the third quarter with $328.6 million in cash equivalents and marketable securities, and an additional $48.7 million raised post-quarter.
- Zariva Nursen has been granted breakthrough therapy designation, which could expedite its regulatory review process.
- The company has compiled extensive data over four years, demonstrating the potential of Zariva Nursen to reduce seizure frequency and improve cognitive and behavioral outcomes in Dravet syndrome patients.
- Stoke Therapeutics Inc (STOK) is actively preparing for a potential U.S. launch of Zariva Nursen, with investments in medical affairs, commercial operations, and market access capabilities.
- The Phase 3 trial for Zariva Nursen is still ongoing, with completion of enrollment not expected until the second half of 2026, delaying potential market entry.
- There are concerns about the elevated CSF protein levels observed in patients, although no clinical manifestations have been associated with these elevations.
- The company reported a net loss of $38.3 million for the third quarter, driven by increased R&D and SG&A expenses.
- There is uncertainty regarding the regulatory pathway and potential expedited approval for Zariva Nursen, as discussions with the FDA are still pending.
- The company faces challenges in ensuring the robustness of its natural history studies and aligning them with regulatory expectations.
Good day and thank you for standing by.
Welcome to the Stoke Therapeutics, 3rd quarter, 2025.
Business and Financial update.
At this time, all participants are in listen-only mode.
After the speaker's presentation, there will be a question-and-answer session.
To ask a question during this session, you need to press star 11 on your telephone.
You would then hear an automated message advising your hand is raised.
To withdraw your question, please press star 11 again.
Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today.
Thomas Leggette, Chief Finan Chief Financial Officer.
Please go ahead.
Good afternoon and welcome to Sto Therapeutics 3rd quarter, 2025 conference call.
I'm Thomas Leggett, Chief Financial Officer at Stoke Therapeutics.
Joining me are Ian Smith, our Chief Executive Officer, and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
